Genetic engineering of a recombinant fusion possessing anti-tumor F(ab′)2 and tumor necrosis factor

This publication has 10 references indexed in Scilit:

• A genetically engineered single-chain FVTNF molecule possesses the anti-tumor immunoreactivity of FV as well as the cytotoxic activity of tumor necrosis factor
  Molecular Immunology, 1995
• A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice.
  Proceedings of the National Academy of Sciences, 1994
• Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant
  Cancer Immunology, Immunotherapy, 1992
• Production of murine V-human cr1 chimeric anti-tag72 antibody using V region cdna amplified by PCR
  Molecular Immunology, 1990
• Phase I study of recombinant human tumor necrosis factor ? in advanced malignant disease
  Cancer Immunology, Immunotherapy, 1989
• Recombinant Human Tumor Necrosis Factor Administered as a 24-Hour Intravenous Infusion. A Phase I and Pharmacologic Study
  JNCI Journal of the National Cancer Institute, 1988
• Genetically engineered immunoglobulins reveal structural features controlling segmental flexibility.
  Proceedings of the National Academy of Sciences, 1988
• Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism.
  Journal of Clinical Oncology, 1988
• Phase I clinical trial of recombinant human tumor necrosis factor
  Cancer Chemotherapy and Pharmacology, 1987
• A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells.
  Proceedings of the National Academy of Sciences, 1987